ECM
PPBT

ETrade Capital Management’s Purple Biotech PPBT Stock Holding History

ETrade Capital Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$76K Buy
87
+26
+43% +$32.1K ﹤0.01% 856
2020
Q2 		$135K Buy
+61
New +$59.9K ﹤0.01% 811

Other funds holding PPBT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Bedel Financial Consulting Indianapolis, Indiana $1.06B AUM 38.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
RFA
Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

ETrade Capital Management's PPBT Position: Q3 2020 in Review

ETrade Capital Management increased its Purple Biotech (PPBT) stake by 43% in Q3 2020, buying an estimated $32.1K and bringing the position to 87 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #856.

ETrade Capital Management first reported a position in PPBT in Q2 2020 and has held it in 2 quarters since. The position peaked at $135K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q3 2020.

  • ETrade Capital Management held 87 shares of Purple Biotech worth $76K as of Q3 2020.
  • ETrade Capital Management bought 26 Purple Biotech shares in Q3 2020, an estimated $32.1K.
  • Purple Biotech made up ﹤0.01% of ETrade Capital Management's portfolio in Q3 2020, its #856 holding.
  • ETrade Capital Management first reported a position in Purple Biotech in Q2 2020 and has held it in 2 quarters since.
  • ETrade Capital Management's Purple Biotech position peaked at $135K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.